Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS
Open Access
- 15 October 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 112 (8), 3434-3443
- https://doi.org/10.1182/blood-2008-02-139824
Abstract
MDS is characterized by ineffective hematopoiesis that leads to peripheral cytopenias. Development of effective treatments has been impeded by limited insight into pathogenic pathways governing dysplastic growth of hematopoietic progenitors. We demonstrate that smad2, a downstream mediator of transforming growth factor–β (TGF-β) receptor I kinase (TBRI) activation, is constitutively activated in MDS bone marrow (BM) precursors and is overexpressed in gene expression profiles of MDS CD34+ cells, providing direct evidence of overactivation of TGF-β pathway in this disease. Suppression of the TGF-β signaling by lentiviral shRNA-mediated down-regulation of TBRI leads to in vitro enhancement of hematopoiesis in MDS progenitors. Pharmacologic inhibition of TBRI (alk5) kinase by a small molecule inhibitor, SD-208, inhibits smad2 activation in hematopoietic progenitors, suppresses TGF-β–mediated gene activation in BM stromal cells, and reverses TGF-β–mediated cell-cycle arrest in BM CD34+ cells. Furthermore, SD-208 treatment alleviates anemia and stimulates hematopoiesis in vivo in a novel murine model of bone marrow failure generated by constitutive hepatic expression of TGF-β1. Moreover, in vitro pharmacologic inhibition of TBRI kinase leads to enhancement of hematopoiesis in varied morphologic MDS subtypes. These data directly implicate TGF-β signaling in the pathobiology of ineffective hematopoiesis and identify TBRI as a potential therapeutic target in low-risk MDS.Keywords
This publication has 57 references indexed in Scilit:
- Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosisBlood, 2007
- Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and InvasivenessPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2007
- Adenoviral-mediated TGF-β1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis developmentExperimental Hematology, 2007
- Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitorsBlood, 2006
- The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurementsNature Biotechnology, 2006
- Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor KinaseIn vivoClinical Cancer Research, 2006
- Hematopoiesis Controlled by Distinct TIF1γ and Smad4 Branches of the TGFβ PathwayCell, 2006
- Functional Analysis of Human Hematopoietic Stem Cell Gene Expression Using ZebrafishPLoS Biology, 2005
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- A gene atlas of the mouse and human protein-encoding transcriptomesProceedings of the National Academy of Sciences of the United States of America, 2004